Aaronson ST, van der Vaart A, Miller T, LaPratt J, Swartz K, Shoultz A, Lauterbach M, Sackeim HA, Suppes T (2023) Single-dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar type II major depressive episodes: a nonrandomized controlled trial. JAMA Psychiat. https://doi.org/10.1001/jamapsychiatry.2023.4685

Article  Google Scholar 

Abbas A, Roth BL (2008) Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. Expert Opin Pharmacother 9(18):3251–3259. https://doi.org/10.1517/14656560802532707

Article  CAS  PubMed  Google Scholar 

Abraham WC, Bear MF (1996) Metaplasticity: the plasticity of synaptic plasticity. Trends Neurosci 19(4):126–130. https://doi.org/10.1016/s0166-2236(96)80018-x

Article  CAS  PubMed  Google Scholar 

Abuzzahab FS Sr, Anderson BJ (1971) A review of LSD treatment in alcoholism. Int Pharmacopsychiatry 6(4):223–235. https://doi.org/10.1159/000468273

Article  PubMed  Google Scholar 

Aday JS, Heifets BD, Pratscher SD, Bradley E, Rosen R, Woolley JD (2022) Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials. Psychopharmacology 239(6):1989–2010. https://doi.org/10.1007/s00213-022-06123-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aleksandrova LR, Phillips AG (2021) Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. Trends Pharmacol Sci 42(11):929–942. https://doi.org/10.1016/j.tips.2021.08.003

Article  CAS  PubMed  Google Scholar 

Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, Ascher J, Russ C, Krishen A, Evins AE (2016) Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 387(10037):2507–2520. https://doi.org/10.1016/S0140-6736(16)30272-0

Article  CAS  PubMed  Google Scholar 

Audenaert K, Van Laere K, Dumont F, Vervaet M, Goethals I, Slegers G, Mertens J, van Heeringen C, Dierckx RA (2003) Decreased 5-HT2a receptor binding in patients with anorexia nervosa. J Nucl Med 44(2):163–169. https://www.ncbi.nlm.nih.gov/pubmed/12571204

Bailer UF, Price JC, Meltzer CC, Mathis CA, Frank GK, Weissfeld L, McConaha CW, Henry SE, Brooks-Achenbach S, Barbarich NC, Kaye WH (2004) Altered 5-HT(2A) receptor binding after recovery from bulimia-type anorexia nervosa: relationships to harm avoidance and drive for thinness. Neuropsychopharmacology 29(6):1143–1155. https://doi.org/10.1038/sj.npp.1300430

Article  CAS  PubMed  Google Scholar 

Barrett FS, Griffiths RR (2018) Classic hallucinogens and mystical experiences: phenomenology and neural correlates. Curr Top Behav Neurosci 36:393–430. https://doi.org/10.1007/7854_2017_474

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barrett FS, Johnson MW, Griffiths RR (2015) Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin. J Psychopharmacol 29(11):1182–1190. https://doi.org/10.1177/0269881115609019

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barrett FS, Bradstreet MP, Leoutsakos JS, Johnson MW, Griffiths RR (2016) The challenging experience questionnaire: characterization of challenging experiences with psilocybin mushrooms. J Psychopharmacol 30(12):1279–1295. https://doi.org/10.1177/0269881116678781

Article  PubMed  PubMed Central  Google Scholar 

Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ (2015) Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol 29(3):289–299. https://doi.org/10.1177/0269881114565144

Article  CAS  PubMed  Google Scholar 

Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, Mennenga SE, O’Donnell K, Owens LT, Podrebarac S, Rotrosen J, Tonigan JS, Worth L (2022) Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiat 79(10):953–962. https://doi.org/10.1001/jamapsychiatry.2022.2096

Article  Google Scholar 

Cameron LP, Tombari RJ, Lu J, Pell AJ, Hurley ZQ, Ehinger Y, Vargas MV, McCarroll MN, Taylor JC, Myers-Turnbull D, Liu T, Yaghoobi B, Laskowski LJ, Anderson EI, Zhang G, Viswanathan J, Brown BM, Tjia M, Dunlap LE, . . . Olson DE (2021) A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature 589(7842):474–479. https://doi.org/10.1038/s41586-020-3008-z

Canal CE, Morgan D (2012) Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model. Drug Test Anal 4(7–8):556–576. https://doi.org/10.1002/dta.1333

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cao D, Yu J, Wang H, Luo Z, Liu X, He L, Qi J, Fan L, Tang L, Chen Z, Li J, Cheng J, Wang S (2022) Structure-based discovery of nonhallucinogenic psychedelic analogs. Science 375(6579):403–411. https://doi.org/10.1126/science.abl8615

Article  CAS  PubMed  Google Scholar 

Carhart-Harris RL (2023) Translational challenges in psychedelic medicine. N Engl J Med 388(5):476–477. https://doi.org/10.1056/NEJMcibr2213109

Article  PubMed  Google Scholar 

Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3(7):619–627. https://doi.org/10.1016/S2215-0366(16)30065-7

Article  PubMed  Google Scholar 

Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, Kaelen M, Giribaldi B, Bloomfield M, Pilling S, Rickard JA, Forbes B, Feilding A, Taylor D, Curran HV, Nutt DJ (2018) Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology 235(2):399–408. https://doi.org/10.1007/s00213-017-4771-x

Article  CAS  PubMed  Google Scholar 

Carhart-Harris RL, Roseman L, Haijen E, Erritzoe D, Watts R, Branchi I, Kaelen M (2018) Psychedelics and the essential importance of context. J Psychopharmacol 32(7):725–731. https://doi.org/10.1177/0269881118754710

Article  PubMed  Google Scholar 

Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ (2021) Trial of psilocybin versus escitalopram for depression. N Engl J Med 384(15):1402–1411. https://doi.org/10.1056/NEJMoa2032994

Article  CAS  PubMed  Google Scholar 

Cavanna F, Muller S, de la Fuente LA, Zamberlan F, Palmucci M, Janeckova L, Kuchar M, Pallavicini C, Tagliazucchi E (2022) Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study. Transl Psychiatry 12(1):307. https://doi.org/10.1038/s41398-022-02039-0

Article  PubMed  PubMed Central  Google Scholar 

Chang-Fong J, Addo J, Dukat M, Smith C, Mitchell NA, Herrick-Davis K, Teitler M, Glennon RA (2002) Evaluation of isotryptamine derivatives at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett 12(2):155–158. https://doi.org/10.1016/s0960-894x(01)00713-2

Article  CAS  PubMed  Google Scholar 

Choi DS, Maroteaux L (1996) Immunohistochemical localisation of the serotonin 5-HT2B receptor in mouse gut, cardiovascular system, and brain. FEBS Lett 391(1–2):45–51. https://doi.org/10.1016/0014-5793(96)00695-3

Article  CAS  PubMed  Google Scholar 

Choi DS, Ward SJ, Messaddeq N, Launay JM, Maroteaux L (1997) 5-HT2B receptor-mediated serotonin morphogenetic functions in mouse cranial neural crest and myocardiac cells. Development 124(9):1745–1755. https://doi.org/10.1242/dev.124.9.1745

Article  CAS  PubMed  Google Scholar 

ClinicalTrials.gov NUN (2023a) Effects of Psilocybin in Anorexia Nervosa. Retrieved 05/22/2023 from https://clinicaltrials.gov/ct2/show/NCT04052568

ClinicalTrials.gov NUN (2023b) Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy. Retrieved 05/22/2023 from https://clinicaltrials.gov/ct2/show/NCT04661514

ClinicalTrials.gov NUN (2023c) Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study. Retrieved 05/22/2023 from https://clinicaltrials.gov/ct2/show/NCT04505189

Cunningham MJ, Bock HA, Serrano IC, Bechand B, Vidyadhara DJ, Bonniwell EM, Lankri D, Duggan P, Nazarova AL, Cao AB, Calkins MM, Khirsariya P, Hwu C, Katritch V, Chandra SS, McCorvy JD, Sames D (2023) Pharmacological Mechanism of the Non-hallucinogenic 5-HT(2A) Agonist Ariadne and Analogs. ACS Chem Neurosci 14(1):119–135. https://doi.org/10.1021/acschemneuro.2c00597

Article  CAS  PubMed  Google Scholar 

Cusin C, Ionescu DF, Pavone KJ, Akeju O, Cassano P, Taylor N, Eikermann M, Durham K, Swee MB, Chang T, Dording C, Soskin D, Kelley J, Mischoulon D, Brown EN, Fava M (2017) Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation. Aust N Z J Psychiatry 51(1):55–64. https://doi.org/10.1177/0004867416631828

Article  PubMed  Google Scholar 

Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, Finan PH, Griffiths RR (2021) Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiat 78(5):481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285

Article  Google Scholar 

Davoudian PA, Shao LX, Kwan AC (2023) Shared and distinct brain regions targeted for immediate early gene expression by ketamine and psilocybin. ACS Chem Neurosci 14(3):468–480. https://doi.org/10.1021/acschemneuro.2c00637

Article  CAS  PubMed  Google Scholar 

de la Fuente Revenga M, Zhu B, Guevara CA, Naler LB, Saunders JM, Zhou Z, Toneatti R, Sierra S, Wolstenholme JT, Beardsley PM, Huntley GW, Lu C, Gonzalez-Maeso J (2021) Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice. Cell Rep 37(3):109836. https://doi.org/10.1016/j.celrep.2021.109836

Article  CAS  PubMed  Google Scholar 

de la Torre R, Farre M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, Cami J (2004) Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit 26(2):137–144. https://doi.org/10.1097/00007691-200404000-00009

Article  PubMed  Google Scholar 

de Wit H, Molla HM, Bershad A, Bremmer M, Lee R (2022) Repeated low doses of LSD in healthy adults: A placebo-controlled, dose-response study. Addict Biol 27(2):e13143. https://doi.org/10.1111/adb.13143

Article